Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Small Cell Lung Carcinoma 146Adenocarcinoma of Lung 71Neoplasms 44Neoplasm Metastasis 34Adenocarcinoma, Bronchiolo-Alveolar 30Colorectal Neoplasms 25Ovarian Neoplasms 24Carcinoma 24Lung Diseases 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Breast Neoplasms 17Mesothelioma 16Thoracic Neoplasms 15Respiratory Tract Neoplasms 15Mesothelioma, Malignant 15Pancreatic Neoplasms 13NSCLC 13Endometrial Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Bronchogenic 12Adenocarcinoma 12Melanoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Brain Neoplasms 10Respiratory Tract Diseases 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nonsquamous Non-small Cell Lung Cancer × Carboplatin × Thoracic × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡